Recent discoveries include:

In 1999, a three-headed turtle was discovered in Tainan, Taiwan, by a villager named Lin Chi-fa. In 2003, a two-headed angulate tortoise was discovered in South Africa, with the only other known case in the region reported in the early 1980s. In 2004, Solomon and Sheba, a two-headed Mediterranean spur-thighed tortoise, was born in Dorchester, England. In 2005, a two-headed olive ridley sea turtle was found in Costa Rica by the World Wildlife Fund. In 2005, a baby turtle of unknown species was also reported in Havana, Cuba, in 2005. In 2006, a two-headed, six-limbed soft-shell turtle in Singapore named "Double Happiness" was also featured on a local television program, and again on another program in late 2006. In December 2021, a living two-headed Greek tortoise named Janus born in 1997 was displayed in the Museum of Natural History of Geneva. As of 2007, there is a fully preserved common snapping turtle named Emily with two heads at the Science Museum of Minnesota. In February 2011, a two-headed turtle was uncovered in Garner, North Carolina. A two-headed Florida redbelly turtle named Gege lived at the Homosassa Springs Wildlife State Park, transferred to a zoo where it spent the rest of its natural life until summer of 2008. A two-headed turtle is currently on display at the Coex Aquarium in Seoul, South Korea. A two-headed turtle was released into the ocean with about 50 other turtles as part of a Broward County, Florida hatching turtle rescue program on July 19, 2012.
Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously. Contraindications
In Europe, use of selexipag together with strong inhibitors of the liver enzyme CYP2C8, such as gemfibrozil, is contraindicated because it increases concentrations of selexipag twofold, and its active metabolite 11-fold, potentially leading to more adverse effects. Adverse effects
The adverse effects of selexipag are similar to those of intravenous prostacyclins used for pulmonary arterial hypertension. Common side effects include headache and jaw pain. An increased risk for hyperthyroidism has also been noted in people taking selexipag. Pharmacology
Mechanism of action
Selexipag and its active metabolite ACT-333679 act on the prostacyclin receptor of lung tissue, with the latter being 37-fold more potent. They are selective for the prostacyclin receptor. Binding to this receptor leads to three major effects: increased vasodilation of the arteries, decreased cell proliferation and inhibition of platelet aggregation, all beneficial in the treatment of pulmonary arterial hypertension. Pharmacokinetics
Selexipag is quickly absorbed from the gut and hydrolyzed in the intestines and the liver to ACT-333679 by carboxylesterases. Absolute bioavailability is about 49%, most likely because of a high first-pass effect. Highest concentrations in the blood plasma are reached after one to three hours for selexipag and after three to four hours for the active metabolite.